Overview of the Gut–Brain Axis: From Gut to Brain and Back Again

Abstract

The gut–brain axis refers to a bidirectional communication pathway linking the gastrointestinal system to the central nervous system. The hardware of this multifaceted pathway takes many forms, at once structural (neurons, microglia, intestinal epithelial cell barrier), chemical (neurotransmitters, enteroendocrine hormones, bacterial metabolites), and cellular (immune signaling, inflammatory pathways). The gut–brain axis is exquisitely influenced by our environment, diet, and behaviors. Here, we will describe recent progress in understanding the gut–brain axis in neurological disease, using Parkinson's disease as a guide. We will see that each component of the gut–brain axis is heavily mediated by intestinal microbiota and learn how gut–brain communication can go awry in microbial dysbiosis.

Keywords

gut–brain axis - microbiome–gut–brain axis - neuroendocrinology - neuroinflammation

Publication History

Article published online:
10 August 2023

• References

• 1 Rutsch A, Kantsjö JB, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol 2020; 11: 604179
• 2 Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology 2021; 160 (05) 1486-1501
• 3 Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells 2019; 8 (12) 1605
• 4 Manfready RA, Engen PA, Verhagen Metman L. et al. Attenuated postprandial GLP-1 response in Parkinson's disease. Front Neurosci 2021; 15: 660942
• 5 Fairbrass KM, Lovatt J, Barberio B, Yuan Y, Gracie DJ, Ford AC. Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut 2022; 71 (09) 1773-1780
• 6 Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med 2018; 24 (04) 392-400
• 7 Kaelberer MM, Buchanan KL, Klein ME. et al. A gut-brain neural circuit for nutrient sensory transduction. Science 2018; 361 (6408) 1219
• 8 Payne SC, Furness JB, Burns O. et al. Anti-inflammatory effects of abdominal vagus nerve stimulation on experimental intestinal inflammation. Front Neurosci 2019; 13: 418
• 9 Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb Cell 2019; 6 (10) 454-481
• 10 Sampson TR, Debelius JW, Thron T. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016; 167 (06) 1469-1480.e12
• 11 Zheng P, Zeng B, Zhou C. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 2016; 21 (06) 786-796
• 12 Kelly JR, Borre Y, O' Brien C. et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res 2016; 82: 109-118
• 13 Bougeard C, Picarel-Blanchot F, Schmid R, Campbell R, Buitelaar J. Prevalence of autism spectrum disorder and co-morbidities in children and adolescents: a systematic literature review. Front Psychiatry 2021; 12: 744709
• 14 Lin CH, Chen CC, Chiang HL. et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. J Neuroinflammation 2019; 16 (01) 129
• 15 Keshavarzian A, Green SJ, Engen PA. et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015; 30 (10) 1351-1360
• 16 Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian rhythm and the gut microbiome. Int Rev Neurobiol 2016; 131: 193-205
• 17 Gruber J, Kennedy BK. Microbiome and longevity: gut microbes send signals to host mitochondria. Cell 2017; 169 (07) 1168-1169
• 18 Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis?. Neurochem Int 2016; 99: 110-132
• 19 Li G, Lin J, Zhang C. et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes 2021; 13 (01) 1968257
• 20 Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne) 2020; 11: 25
• 21 Valles-Colomer M, Falony G, Darzi Y. et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019; 4 (04) 623-632
• 22 Manfready RA, Forsyth CB, Voigt RM, Hall DA, Goetz CG, Keshavarzian A. Gut-brain communication in Parkinson's disease: enteroendocrine regulation by GLP-1. Curr Neurol Neurosci Rep 2022; 22 (07) 335-342
• 23 Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification?. Prog Neurobiol 2016; 145-146: 98-120
• 24 Heppner KM, Kirigiti M, Secher A. et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015; 156 (01) 255-267
• 25 Bertilsson G, Patrone C, Zachrisson O. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86 (02) 326-338
• 26 Nuamnaichati N, Parichatikanond W, Mangmool S. Cardioprotective effects of glucagon-like peptide-1 (9–36) against oxidative injury in H9c2 cardiomyoblasts: Potential role of the PI3K/akt/NOS pathway. J Cardiovasc Pharmacol 2022; 79 (01) e50-e63
• 27 Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology 2018; 136 (Pt B): 260-270
• 28 Athauda D, Maclagan K, Skene SS. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390 (10103): 1664-1675
• 29 Caputi V, Giron MC. Microbiome-gut-brain axis and toll-like receptors in Parkinson's disease. Int J Mol Sci 2018; 19 (06) 1689
• 30 Forsyth CB, Shannon KM, Kordower JH. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011; 6 (12) e28032
• 31 Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20 (01) 197-216
• 32 Perez-Pardo P, Dodiya HB, Engen PA. et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut 2019; 68 (05) 829-843
• 33 Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008; 22 (05) 453-464
• 34 Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J Exp Med 2019; 216 (01) 41-59
• 35 Noelker C, Morel L, Lescot T. et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013; 3 (01) 1393
• 36 Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 2017; 11: 63
• 37 Gordon R, Albornoz EA, Christie DC. et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 2018; 10 (465) eaah4066
• 38 Codolo G, Plotegher N, Pozzobon T. et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One 2013; 8 (01) e55375
• 39 Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev 2015; 265 (01) 35-52
• 40 Hanslik KL, Ulland TK. The role of microglia and the Nlrp3 inflammasome in Alzheimer's disease. Front Neurol 2020; 11: 570711
• 41 Cruz-Pereira JS, Rea K, Nolan YM, O'Leary OF, Dinan TG, Cryan JF. Depression's unholy trinity: dysregulated stress, immunity, and the microbiome. Annu Rev Psychol 2020; 71 (01) 49-78
• 42 Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun 2011; 25 (02) 221-229
• 43 Lee CH, Giuliani F. The role of inflammation in depression and fatigue. Front Immunol 2019; 10: 1696
• 44 Foster JA, Baker GB, Dursun SM. The relationship between the gut microbiome-immune system-brain axis and major depressive disorder. Front Neurol 2021; 12: 721126
• 45 Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol 2014; 14 (10) 667-685
• 46 Agirman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis. Science 2021; 374 (6571) 1087-1092
• 47 Louveau A, Smirnov I, Keyes TJ. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523 (7560) 337-341
• 48 Benakis C, Brea D, Caballero S. et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med 2016; 22 (05) 516-523
• 49 Schwartz K, Boles BR. Microbial amyloids – functions and interactions within the host. Curr Opin Microbiol 2013; 16 (01) 93-99
• 50 Yuki N, Susuki K, Koga M. et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004; 101 (31) 11404-11409
• 51 Abdel-Gadir A, Stephen-Victor E, Gerber GK. et al. Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy. Nat Med 2019; 25 (07) 1164-1174
• 52 Biton M, Haber AL, Rogel N. et al. T helper cell cytokines modulate intestinal stem cell renewal and differentiation. Cell 2018; 175 (05) 1307-1320.e22
• 53 Traxinger BR, Richert-Spuhler LE, Lund JM. Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry. Mucosal Immunol 2022; 15 (03) 398-407
• 54 Jamwal DR, Laubitz D, Harrison CA. et al. Intestinal epithelial expression of MHCII determines severity of chemical, T-cell–induced, and infectious colitis in mice. Gastroenterology 2020; 159 (04) 1342-1356.e6
• 55 Lui PP, Cho I, Ali N. Tissue regulatory T cells. Immunology 2020; 161 (01) 4-17
• 56 Hegazy AN, West NR, Stubbington MJT. et al; Oxford IBD Cohort Investigators. Circulating and tissue-resident CD4+ T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology 2017; 153 (05) 1320-1337.e16
• 57 Smith PM, Howitt MR, Panikov N. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341 (6145) 569-573
• 58 Campbell C, McKenney PT, Konstantinovsky D. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 2020; 581 (7809) 475-479
• 59 Ito M, Komai K, Mise-Omata S. et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature 2019; 565 (7738) 246-250
• 60 Choi J, Kim BR, Akuzum B, Chang L, Lee JY, Kwon HK. TREGking from gut to brain: the control of regulatory T cells along the gut-brain axis. Front Immunol 2022; 13: 916066
• 61 Jena PK, Sheng L, Di Lucente J, Jin LW, Maezawa I, Wan YY. Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity. FASEB J 2018; 32 (05) 2866-2877
• 62 Baloni P, Funk CC, Yan J. et al; Alzheimer's Disease Metabolomics Consortium. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer's disease. Cell Rep Med 2020; 1 (08) 100138
• 63 Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984; 311 (26) 1649-1652
• 64 Yanovsky Y, Schubring SR, Yao Q. et al. Waking action of ursodeoxycholic acid (UDCA) involves histamine and GABAA receptor block. PLoS One 2012; 7 (08) e42512
• 65 Poole DP, Godfrey C, Cattaruzza F. et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22 (07) 814-825 , e227–e228
• 66 Latorre R, Sternini C, De Giorgio R, Greenwood-Van Meerveld B. Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol Motil 2016; 28 (05) 620-630
• 67 Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014; 221 (01) T31-T41
• 68 Cryan JF, O'Riordan KJ, Cowan CSM. et al. The microbiota-gut-brain axis. Physiol Rev 2019; 99 (04) 1877-2013
• 69 Terry N, Margolis KG. Serotonergic mechanisms regulating the GI tract: Experimental evidence and therapeutic relevance. In: Gastrointestinal Pharmacology. Vol 239. Switzerland: Springer International Publishing AG; 2017: 319-342
• 70 Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017; 4 (05) 409-418
• 71 Aaldijk E, Vermeiren Y. The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer's disease: a narrative review. Ageing Res Rev 2022; 75: 101556
• 72 Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JAN. Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 1984; 43 (06) 1574-1581
• 73 Sheline YI, Snider BJ, Beer JC. et al. Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: a controlled clinical trial. Neurology 2020; 95 (19) e2658-e2665
• 74 Kessing LV, Søndergård L, Forman JL, Andersen PK. Antidepressants and dementia. J Affect Disord 2009; 117 (1-2): 24-29
• 75 Alboni S, van Dijk RM, Poggini S. et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry 2017; 22 (04) 635
• 76 McVey Neufeld KA, Bienenstock J, Bharwani A. et al. Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling. Sci Rep 2019; 9 (01) 14290-11
• 77 Reigstad CS, Salmonson CE, Rainey III JF. et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 2015; 29 (04) 1395-1403
• 78 Clarke G, McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012; 3: 90
• 79 Hartstra AV, Schüppel V, Imangaliyev S. et al. Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome. Mol Metab 2020; 42: 101076
• 80 Zhu F, Guo R, Wang W. et al. Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry 2020; 25 (11) 2905-2918
• 81 Yano JM, Yu K, Donaldson GP. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161 (02) 264-276
• 82 Noristani HN, Verkhratsky A, Rodríguez JJ. High tryptophan diet reduces CA1 intraneuronal β-amyloid in the triple transgenic mouse model of Alzheimer's disease. Aging Cell 2012; 11 (05) 810-822
• 83 Jackson A, Forsyth CB, Shaikh M. et al. Diet in Parkinson's disease: critical role for the microbiome. Front Neurol 2019; 10: 1245
• 84 Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008; 29 (06) 322-329
• 85 Tanner CM, Kamel F, Ross GW. et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011; 119 (06) 866-872
• 86 Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci 2012; 69 (18) 2999-3013
• 87 Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol Sci 2009; 30 (09) 475-483
• 88 Więckowska-Gacek A, Mietelska-Porowska A, Wydrych M, Wojda U. Western diet as a trigger of Alzheimer's disease: from metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Res Rev 2021; 70: 101397
• 89 Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe 2018; 23 (06) 705-715
• 90 Maraki MI, Yannakoulia M, Stamelou M. et al. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Mov Disord 2019; 34 (01) 48-57
• 91 Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. 2012 Accessed June 20, 2023 at: http://nrs.harvard.edu/urn-3:HUL.InstRepos:41247278
• 92 Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson's disease. Mov Disord 2012; 27 (06) 771-774
• 93 Hoyles L, Snelling T, Umlai UK. et al. Microbiome–host systems interactions: Protective effects of propionate upon the blood–brain barrier. 2018 Accessed June 20, 2023 at: http://hdl.handle.net/10044/1/57884
• 94 van de Wouw M, Boehme M, Lyte JM. et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations. J Physiol 2018; 596 (20) 4923-4944
• 95 Christ A, Günther P, Lauterbach MAR. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 2018; 172 (1-2): 162-175.e14
• 96 Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 2015; 7: 52
• 97 Tőzsér J, Benkő S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1β production. Mediators Inflamm 2016; 2016: 5460302-5460316
• 98 Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement 2015; 11 (09) 1007-1014
• 99 Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab 2014; 19 (02) 181-192
• 100 Maswood N, Young J, Tilmont E. et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101 (52) 18171-18176
• 101 Youm YH, Nguyen KY, Grant RW. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21 (03) 263-269
• 102 Youm YH, Grant RW, McCabe LR. et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 2013; 18 (04) 519-532
• 103 Fann DY, Santro T, Manzanero S. et al. Intermittent fasting attenuates inflammasome activity in ischemic stroke. Exp Neurol 2014; 257: 114-119
• 104 Moon M, Kim HG, Hwang L. et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 2009; 15 (04) 332-347
• 105 Mason GM, Lokhandwala S, Riggins T, Spencer RMC. Sleep and human cognitive development. Sleep Med Rev 2021; 57: 101472
• 106 Sen P, Molinero-Perez A, O'Riordan KJ, McCafferty CP, O'Halloran KD, Cryan JF. Microbiota and sleep: awakening the gut feeling. Trends Mol Med 2021; 27 (10) 935-945
• 107 Pires GN, Bezerra AG, Tufik S, Andersen ML. Effects of acute sleep deprivation on state anxiety levels: a systematic review and meta-analysis. Sleep Med 2016; 24: 109-118
• 108 Koch CE, Leinweber B, Drengberg BC, Blaum C, Oster H. Interaction between circadian rhythms and stress. Neurobiol Stress 2016; 6 (C): 57-67
• 109 Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015; 9: 392
• 110 Zanini MA, Castro J, Cunha GR. et al. Abnormalities in sleep patterns in individuals at risk for psychosis and bipolar disorder. Schizophr Res 2015; 169 (1-3): 262-267
• 111 Hyun MK, Baek Y, Lee S. Association between digestive symptoms and sleep disturbance: a cross-sectional community-based study. BMC Gastroenterol 2019; 19 (01) 34
• 112 Ogawa Y, Miyoshi C, Obana N. et al. Gut microbiota depletion by chronic antibiotic treatment alters the sleep/wake architecture and sleep EEG power spectra in mice. Sci Rep 2020; 10 (01) 19554
• 113 Yu L, Han X, Cen S. et al. Beneficial effect of GABA-rich fermented milk on insomnia involving regulation of gut microbiota. Microbiol Res 2020; 233: 126409
• 114 Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol 2013; 13 (03) 190-198
• 115 Ruben MD, Wu G, Smith DF. et al. A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine. Sci Transl Med 2018; 10 (458) eaat8806
• 116 Bishehsari F, Engen PA, Voigt RM. et al. Abnormal eating patterns cause circadian disruption and promote alcohol-associated colon carcinogenesis. Cell Mol Gastroenterol Hepatol 2020; 9 (02) 219-237
• 117 Forsyth CB, Shaikh M, Bishehsari F. et al. Alcohol feeding in mice promotes colonic hyperpermeability and changes in colonic organoid stem cell fate. Alcohol Clin Exp Res 2017; 41 (12) 2100-2113
• 118 Summa KC, Voigt RM, Forsyth CB. et al. Disruption of the circadian clock in mice increases intestinal permeability and promotes alcohol-induced hepatic pathology and inflammation. PLoS One 2013; 8 (06) e67102
• 119 Swanson GR, Gorenz A, Shaikh M. et al. Night workers with circadian misalignment are susceptible to alcohol-induced intestinal hyperpermeability with social drinking. Am J Physiol Gastrointest Liver Physiol 2016; 311 (01) G192-G201
• 120 Moravcová S, Pačesová D, Melkes B. et al. The day/night difference in the circadian clock's response to acute lipopolysaccharide and the rhythmic Stat3 expression in the rat suprachiasmatic nucleus. PLoS One 2018; 13 (09) e0199405
• 121 Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. Exp Neurol 2013; 243: 45-56
• 122 Heintz-Buschart A, Pandey U, Wicke T. et al. The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord 2018; 33 (01) 88-98
• 123 Moreno-Indias I, Torres M, Montserrat JM. et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J 2015; 45 (04) 1055-1065
• 124 Li Y, Zhang B, Zhou Y. et al. Gut microbiota changes and their relationship with inflammation in patients with acute and chronic insomnia. Nat Sci Sleep 2020; 12: 895-905
• 125 Zhang Y, Xie B, Chen X, Zhang J, Yuan S. A key role of gut microbiota-vagus nerve/spleen axis in sleep deprivation-mediated aggravation of systemic inflammation after LPS administration. Life Sci 2021; 265: 118736
• 126 Kaczmarek JL, Musaad SM, Holscher HD. Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota. Am J Clin Nutr 2017; 106 (05) 1220-1231
• 127 Thompson RS, Vargas F, Dorrestein PC, Chichlowski M, Berg BM, Fleshner M. Dietary prebiotics alter novel microbial dependent fecal metabolites that improve sleep. Sci Rep 2020; 10 (01) 3848
• 128 Petrov ME, Whisner CM, McCormick D, Todd M, Reifsnider E. Sleep-wake patterns during infancy are associated with gut microbial community structure in toddlerhood (Abstract Supplement 0243). Sleep (Basel) 2019; 42 (01) A100
• 129 Lightman SL, Birnie MT, Conway-Campbell BL. Dynamics of ACTH and cortisol secretion and implications for disease. Endocr Rev 2020; 41 (03) 470-490
• 130 Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med 2008; 8 (04) 274-281
• 131 Dodiya HB, Forsyth CB, Voigt RM. et al. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis 2020; 135: 104352
• 132 Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 2003; 110 (05) 517-536
• 133 Dogra N, Mani RJ, Katare DP. The gut-brain axis: two ways signaling in Parkinson's disease. Cell Mol Neurobiol 2022; 42 (02) 315-332
• 134 Holmqvist S, Chutna O, Bousset L. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014; 128 (06) 805-820
• 135 Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD. Exploring Braak's hypothesis of Parkinson's disease. Front Neurol 2017; 8: 37
• 136 Svensson E, Horváth-Puhó E, Thomsen RW. et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015; 78 (04) 522-529
• 137 Kelly LP, Carvey PM, Keshavarzian A. et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 2014; 29 (08) 999-1009
• 138 Liddle RA. Parkinson's disease from the gut. Brain Res 2018; 1693 (Pt B): 201-206
• 139 Shannon KM, Keshavarzian A, Mutlu E. et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012; 27 (06) 709-715
• 140 Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012; 27 (06) 716-719
• 141 Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson's disease: subjective symptoms, objective markers, and new perspectives. Mov Disord 2017; 32 (01) 94-105
• 142 Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015; 14 (06) 625-639
• 143 Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson's disease: a hypothesis. J Parkinsons Dis 2019; 9 (Suppl. 02) S281-S295
• 144 Guo M, Wang J, Zhao Y. et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease. Brain 2020; 143 (05) 1476-1497
• 145 Ding XB, Wang XX, Xia DH. et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease. Nat Med 2021; 27 (03) 411-418
• 146 Pal G, Ramirez V, Engen PA. et al. Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease. NPJ Parkinsons Dis 2021; 7 (01) 111
• 147 Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett 2008; 29 (01) 117-124
• 148 Manosso LM, Lin J, Carlessi AS. et al. Sex-related patterns of the gut-microbiota-brain axis in the neuropsychiatric conditions. Brain Res Bull 2021; 171: 196-208
• 149 Hao WZ, Li XJ, Zhang PW, Chen JX. A review of antibiotics, depression, and the gut microbiome. Psychiatry Res 2020; 284: 112691
• 150 Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev 2019; 102: 13-23
• 151 Castro-Nallar E, Bendall ML, Pérez-Losada M. et al. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. PeerJ 2015; 3: e1140
• 152 Golofast B, Vales K. The connection between microbiome and schizophrenia. Neurosci Biobehav Rev 2020; 108: 712-731
• 153 Zheng P, Zeng B, Liu M. et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv 2019; 5 (02) eaau8317
• 154 Fiorentino M, Sapone A, Senger S. et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism 2016; 7 (01) 49
• 155 Asbjornsdottir B, Snorradottir H, Andresdottir E. et al. Zonulin-dependent intestinal permeability in children diagnosed with mental disorders: a systematic review and meta-analysis. Nutrients 2020; 12 (07) 1982
• 156 Alabdali A, Al-Ayadhi L, El-Ansary A. Association of social and cognitive impairment and biomarkers in autism spectrum disorders. J Neuroinflammation 2014; 11 (01) 4